Intermittent dasatinib plus quercetin therapy improves fibrosis stage and resolves MASH in a phase‑2 double‑blind RCT

The Question

Cellular senescence drives liver inflammation and scarring, yet its therapeutic relevance in human metabolic dysfunction‑associated steatohepatitis (MASH) has never been tested. Researchers wondered whether periodically clearing senescent cells could blunt fibrosis and improve disease activity in patients already showing fibrotic changes.

The Experiment

Lead author Koning and colleagues from the Department of Gastroenterology and Hepatology conducted a phase‑2, double‑blind, randomized, placebo‑controlled trial. Thirty‑one participants (median age 56 years; 76 % male; 58 % with type 2 diabetes) were allocated 1:1 to receive either dasatinib 100 mg + quercetin 1,000 mg or matching placebo. The regimen consisted of three consecutive daily doses per week for three weeks, repeated across three 7‑week cycles.

Primary efficacy was assessed by paired liver biopsies, focusing on ≥1‑stage fibrosis improvement without MASH worsening. Secondary outcomes included MASH resolution, change in NAFLD Activity Score, and single‑nucleus RNA sequencing of liver tissue to quantify senescence and fibrotic gene signatures as well as fibrogenic cell populations.

What They Found

Fibrosis improvement occurred in 47 % of the D + Q group versus 7 % with placebo (P = 0.02). MASH resolution was reported in 53 % of treated participants compared with 7 % on placebo (P = 0.02). The NAFLD Activity Score fell by –1.43 ± 1.22 in the active arm, whereas the placebo arm showed a –0.39 ± 0.77 change (P = 0.012). Transcriptomic analysis revealed lowered senescence and fibrotic gene signatures and a contraction of fibrogenic cell populations among those receiving D + Q.

Why It Matters

Senescent hepatic cells secrete pro‑fibrotic cytokines that perpetuate extracellular matrix deposition. By intermittently targeting these cells, dasatinib plus quercetin appears to reset the fibrotic signaling network, allowing the liver to remodel toward a healthier architecture. Demonstrating this effect in a human trial opens a new avenue for senolytic strategies beyond preclinical models, suggesting that periodic senescent‑cell clearance could become a component of metabolic liver disease management.

Study Limitations

• The cohort was small and predominantly male, limiting generalizability to broader populations.


• Follow‑up extended only through the treatment cycles; long‑term durability of fibrosis regression remains unknown.


• Biopsy‑based endpoints, while rigorous, capture a snapshot and may miss subtle functional improvements.

Practical Application

It's too early to apply this protocol to a personal regimen. Future work must confirm safety and efficacy in larger, more diverse groups, demonstrate sustained benefits after treatment cessation, and clarify optimal dosing intervals before healthy adults can consider intermittent dasatinib plus quercetin for performance‑related goals.

Disclaimer: This article is for informational and educational purposes only. The information presented does not constitute medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before modifying your diet, supplementation, or exercise routines. The scientific studies cited reflect the state of knowledge at their publication date and may be subject to revision.